On Tuesday shares of AbbVie Inc. (NYSE:ABBV) closed at $64.81. Company’s sales growth for last 5 years was 7.00% and EPS growth for next 5 years is recorded as 14.90%. AbbVie Inc (NYSE:ABBV) announced 17 abstractsfrom studies of the company’s oncology pipeline are being presented at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO), May 29 – June 2, in Chicago. Notably, data will be presented from investigational studies of venetoclax, a B-cell lymphoma-2 (BCL-2) selective inhibitor, in relapsed or refractory multiple myeloma (R/R MM) patients, and veliparib (ABT-888), a poly (adenosine diphosphate [ADP]–ribose) polymerase (PARP) inhibitor, in advanced non-small cell lung cancer (NSCLC) patients with a history of smoking – a factor identified as the number one risk for lung cancer in the United States.
Synageva BioPharma Corp. (NASDAQ:GEVA) in last trading activity moved down -0.18% to close at $212.42. Company weekly performance is 121.57% while its quarterly performance stands at 102.42%. Synageva BioPharma Corp. (NASDAQ:GEVA) is -2.07% away from its 52 week high. Alexion Pharmaceuticals, and Synageva BioPharma Corp. (NASDAQ:GEVA) declared that they have reached a definitive agreement following which Alexion will acquire Synageva for consideration of $115 in cash and 0.6581 Alexion shares, for each share of Synageva, implying a total per share value of $230 based on the nine day volume-weighted average closing price of Alexion stock through May 5, 2015.
On Tuesday shares of Delta Air Lines, Inc. (NYSE:DAL) closed at $46.10. Company’s sales growth for last 5 years was 7.50% and EPS growth for next 5 years is recorded as 19.35%. Delta Airlines, Inc. (NYSE:DAL) is citing the continued devaluation of the Yen as well as fare declines for its decision to cut flights to the Northern Marianas this winter.
Lumenis Ltd. (NASDAQ:LMNS) has institutional ownership stands at 22.40%. In last trading activity company’s stock closed at $11.13. On the ratings front, analysts at Maxim Group initiated coverage on shares of Lumenis, they set a “buy” rating and a $18.00 price target on the stock.
Cisco Systems, Inc. (NASDAQ:CSCO) in last trading activity increased 0.07% to close at $29.23. Company weekly performance is 1.18% while its quarterly performance stands at 7.14%. Cisco Systems, Inc. (NASDAQ:CSCO) is -2.83% away from its 52 week high. Cisco Systems Inc. (NASDAQ:CSCO) is expected to report third-quarter earnings after the market close on Wednesday.